Sessions

THE CONTINUED RISE & APPLICATION OF AUTOLOGOUS THERAPIES
THE POTENTIAL & PROMISE OF ALLOGENEIC
THE EXPONENTIAL GROWTH OF GENE THERAPY & IT’S FUTURE POTENTIAL

THE CONTINUED RISE & APPLICATION OF AUTOLOGOUS THERAPIES

01 Sep 2022
13:30
SPONSORED BY
Invetech
SCTbio

13:30 – CHAIR INTRODUCTION

Chair: Michael Leek, Executive Chairman & Founder, TC BioPharm

 

13:35 – CASE STUDY: ENGINEERING THE GAMMA DELTA TCR FOR AN INNOVATIVE TUMOUR SPECIFIC CELL THERAPY

Speaker: Mark Throsby, Chief Scientific Officer, Gadeta

 

13:50 – CASE STUDY: HELPING PATIENTS TO REGAIN CONTROL: PHASE I STUDY RESULTS FOR SKELETAL MUSCLE REGENERATION 

Speaker: Jenny Prange, Head of GMP Production, Chief Scientific Officer & Co-Founder, MUVON Therapeutics

 

14:05 – CASE STUDY: KORUSTM: TRANSFORMING AUTOLOGOUS CELL THERAPY MANUFACTURING VIA ELUTRIATION

Speaker: Michelle Duquette, Director – Cell Therapy, Invetech

 

14:20 – CASE STUDY: AUTOLOGOUS CELL THERAPY – THE JOURNEY FROM TECH TRANSFER TO CLINICAL MANUFACTURING

Speaker: Rachel Yao, Associate Director, SOTIO Biotech Inc

 

14:35 – Q&A WITH SESSION SPEAKERS

Speakers:

Mark Throsby, Chief Scientific Officer, Gadeta

Jenny Prange, Head of GMP Production, Chief Scientific Officer & Co-Founder, MUVON Therapeutics

Michelle Duquette, Director – Cell Therapy, Invetech

Rachel Yao, Associate Director, SOTIO Biotech Inc

Speakers

Michael Leek
Executive Chairman & Founder
TC Biopharm
Mark Throsby
Chief Scientific Officer
Gadeta
Jenny Prange
CSO and Co-Founder
Muvon Therapeutics
Michelle Duquette
Director, Business Development – Cell Therapy
Invetech
Rachel Yao
Associate Director Technical Operations
SOTIO Biotech Inc